BIOMAT Database Logo BIOMAT Database Logo

[Combined treatment in patients with carcinoma in situ of the urinary bladder using intravesical pirarubicin, irradiation and hyperthermia]. 1990

T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Department of Radiology, National Hospital Shikoku Cancer Center.

The treatment with hyperthermia in combination with radiation and intravesical pirarubicin (THP-ADM) was preliminary investigated in 5 patients with urinary bladder carcinoma in situ. Following intravesical administration of 30 mg THP-ADM, external irradiation of 3.0 Gy was delivered to the urinary bladder. Immediately then, hyperthermia using Thermotron RF-8 was performed for 50 min (intravesical temperature: 42-43 degrees C for 35 min). After five courses of the treatment, complete response has been maintained for 6, 8, and 9 months in 3 patients. However, in a patient with complete response, urinary cytology became positive in the 6th month after the treatment. In the remaining patient treatment was interrupted after only 3 courses due to urinary irritation, urinary cytology didn't become negative. The side effects of the combined treatment were limited to the transient symptoms of bladder irritation in all patients and thermal burn in 2 patients. These preliminary results suggest that this combined treatment may represent an effective conservative therapy for patients with urinary bladder carcinoma in situ.

UI MeSH Term Description Entries
D006979 Hyperthermia, Induced Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs. Fever Therapy,Hyperthermia, Local,Hyperthermia, Therapeutic,Thermotherapy,Induced Hyperthermia,Therapeutic Hyperthermia,Therapy, Fever,Local Hyperthermia
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002278 Carcinoma in Situ A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane. Carcinoma, Intraepithelial,Carcinoma, Preinvasive,Intraepithelial Neoplasms,Neoplasms, Intraepithelial,Intraepithelial Carcinoma,Intraepithelial Neoplasm,Neoplasm, Intraepithelial,Preinvasive Carcinoma
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Diagnosing the location of carcinoma in situ (CIS) of the urinary bladder using pirarubicin hydrochloride.
January 2005, Urologia internationalis,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
January 2011, Urologic oncology,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder.
January 1984, Scandinavian journal of urology and nephrology,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Intravesical mitomycin C for carcinoma in situ of the urinary bladder.
January 1990, Scandinavian journal of urology and nephrology,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Intravesical instillations and cancer-specific survival in patients with primary carcinoma in situ of the urinary bladder.
April 2017, Scandinavian journal of urology,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party.
June 2009, World journal of urology,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
[Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
February 1987, Wiener klinische Wochenschrift,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
[Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
January 2017, Der Urologe. Ausg. A,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later.
January 1984, European urology,
T Takechi, and M Kawamura, and H Nakagawa, and S Inatsuki, and K Akiyama, and M Yano, and Y Sumiyoshi, and K Mandai, and S Moriwaki, and M Kataoka
Preoperative hyperthermia combined with chemotherapy and irradiation for the treatment of patients with esophageal carcinoma.
January 1995, Tumori,
Copied contents to your clipboard!